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2Abstract
Prostate cancer is the most frequently diagnosed form of cancer and the second leading 
cause of cancer related deaths in the United States.  Increased consumption of soy is thought to 
reduce the risk for this disease.  More specifically, the isoflavones found in soy are responsible, 
in part, for these anticancer effects.   Isoflavones are organic compounds found in soy and other 
legumes and it is thought that methylated isoflavones (glycitein, biochanin A, formononetin) 
may have greater anticancer activity than those without methyl groups (genistein, daidzein, 
equol).  However, the majority of studies, to date, have focused primarily on the nonmethylated  
isoflavones, genistein and daidzein.  Epidemiological evidence also suggests that the anticancer 
effects of soy may be greatest during the precancerous stages of prostate cancer.  Few studies, 
however, have examined the impact of soy isoflavones during this precancerous stage.  This 
study examined the antiproliferative effects of methylated and nonmethylated soy isoflavones 
using a precancerous prostate cell line (WPE1-NB14).  The precancerous prostate cells were 
treated with the six different soy isoflavones, three methylated and three nonmethylated, in 
different concentrations (0-50µM).  Cell viability was determined using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay.  This assay uses MTT to 
color the living cells in order to determine the cell viability.  The results of this study suggest that 
methylated isoflavones reduced precancerous cell viability to a greater extent than 
nonmethylated isoflavones and indicate that the methyl group does contribute to the anticancer 
effects of soy isoflavones in precancerous prostate cells.  While most studies focus on 
nonmethylated isoflavones because they are the most abundant, they are not necessarily the most 
bioactive.  This study demonstrates the positive impact methylated isoflavones can have on 
prostate cancer prevention.  
3Introduction
Prostate cancer is the most frequently diagnosed and the second leading cause of cancer 
related deaths in the United States (1).  The incidence of prostate cancer in Asian populations, 
however, is tenfold lower than that of western cultures.  These observed differences in prostate 
cancer incidence are thought to be due, in part, to increased consumption of soy in Asian
countries (2).  Isoflavones are the specific compounds found in soy that are thought to contribute 
to the reduction of prostate cancer in men. The predominant isoflavones found in soy are 
genistein, daidzein, and glycitein, comprising 50, 40, and 10% of the total isoflavone profile, 
respectively.  Although these compounds are structurally similar, studies suggest that each 
individual isoflavone inhibits cancer processes such as proliferation via different mechanisms.  
For example, genistein has been shown to inhibit proliferation at high concentrations yet induce 
proliferation at low 
concentrations in prostate 
cells (3).  Studies on 
glycitein, however, show that 
this isoflavone significantly 
reduces the proliferation of 
prostate cells at lower 
concentrations than other soy 
isoflavones (4).  Glycitein is 
unique in that it is the only 
isoflavone found in soy with 
a methoxy group.  
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Figure 1. Isoflavone Structures
4Interestingly, methylated flavones have been shown to be more bioavailable and biologically 
stable than nonmethylated flavones (5-6).  However to date, the anticancer effects of methylated 
isoflavones such as glycitein found in soy, and biochanin A and formononetin found in red 
clover, have not been well characterized.  This study examined the antiproliferative effects of 
methylated and nonmethylated isoflavones using a precancerous prostate epithelial cell line 
(WPE1-NB14). The central hypothesis of this research is that methylated isoflavones 
reduce the cell viability of the WPE1-NB14 cell line to a greater extent than the 
nonmethylated isoflavones.
Literature Review
Prostate cancer is the most diagnosed and the second leading cause of cancer related 
death among American males (1).  The single most predictive risk factor for prostate cancer is 
age.  Therefore, as life expectancy increases, the total number of predicted cases also increases
(7).  Prostate cancer development can take years or even decades to manifest and its development 
occurs in stages of premalignant lesions called prostatic intraepithelial neoplasia (PIN).
Approximately one third of PIN cases develop into prostate cancer and its presence in the 
prostate greatly increases the risk of acquiring this disease (7).  PIN is subsequently divided into 
two grades, low grade 
PIN (LGPIN) and 
high grade PIN 
(HGPIN).  LGPIN is 
characterized 
by irregular spacing 
Figure 2. Progression of Prostate Cancer
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5of epithelial cells, cell growth and stratification (7) and it has been observed in men in their 20s 
(8).  HGPIN is characterized by even more epithelial cell crowding and stratification (7) and has 
been observed in men as early as 40 years old (8-9).  Due to the prolonged latency of PIN, 
strategies that target this precancerous lesion in the prostate may reverse or delay the onset of 
prostate cancer.  
American and European males have a tenfold increase in the risk of prostate cancer 
development as compared with East Asian countries (10-11).  The observed difference in the 
prevalence of prostate cancer among Asian men and American men may be due, in part, to 
differences in soy consumption.  Interestingly, Japanese men that immigrate to the US appear to 
have a higher risk for prostate cancer than those who remained in Japan (12).  This observation 
suggests that environmental factors, such as diet, play a pivotal role in the risk for prostate 
cancer. Several epidemiological studies have been conducted to examine the effect of soy 
consumption on the prevalence of prostate cancer.  Kurahashi et al. (2) showed an inverse 
relationship between the amount of soy consumed in the diet and the risk of developing prostate 
cancer in Japanese men.  It has been widely thought that isoflavones found in soy contribute, in 
part, to the reduced risk of prostate cancer.  In fact, men with the highest intake of isoflavones 
had a reduced risk for prostate cancer compared to the men with lower isoflavone intakes (2).  
Japanese men consuming a traditional diet tend to have ten to one hundredfold greater 
concentrations of plasma isoflavones than Western men (10-11) that do not consume soy.  
Studies suggest that increased consumption of soy reduces the risk of HGPIN and 
prostate cancer rather than the initial LGPIN lesions (2).  The incidence of LGPIN appears to be
equivalent in both American and Japanese men; however, a greater incidence of HGPIN and 
prostate cancer is observed in American men (13-14).  These observations suggest that 
6consumption of soy is most beneficial during the precancerous stages of the prostate 
carcinogenic process.  In fact, several epidemiological studies suggest that a diet rich in soy and 
soy isoflavones may prevent prostate cancer during noncancerous and precancerous stages of the 
carcinogenic process and that during advanced disease, exposure to soy isoflavones may no 
longer be beneficial (14-17).
The anticancer effects of genistein and daidzein have been extensively studied in prostate 
cancer cell models (18-27).  Although structurally similar, genistein and daidzein differ in the 
intensity and mechanisms of inhibiting tumor and cellular growth and proliferation.  Several 
studies show that low concentrations of genistein increase cell proliferation while higher
concentrations greatly inhibit proliferation (3, 18).  Furthermore, genistein has been shown to 
induce cell cycle arrest in the G2 phase as well as increase apoptosis (28).  However, daidzein 
and a metabolite of daidzein, equol, have been shown to reduce cell proliferation in prostate 
cancer cells (29) and induce cell cycle arrest in G0/G1 phase (30) rather than the G2 phase as 
observed with genistein.  In vivo studies show that genistein reduces the formation of poorly 
differentiated tumors in the prostate of a transgenic mouse model (TRAMP).  This reduction in 
tumors was greatest in the mice that were exposed to genistein throughout life (27).  
The anticancer effects of the soy isoflavone glycitein have not been well studied.  
However, studies report that this minor soy isoflavone may be more bioactive than genistein and 
daidzein (4, 31).  Glycitein has been shown to significantly reduce the proliferation of 
noncancerous prostate cell lines at concentrations tenfold less than genistein and daidzein.  
Interestingly, glycitein is the only isoflavone with a methoxy group.  Studies suggest that
flavones with methoxy groups appear to have more beneficial qualities than their nonmethylated 
counterparts including the enhanced ability to resist metabolism, a greater biological stability, 
7and improved intestinal transport (5-6).  However, the bioactivity and anticancer activity of 
methylated isoflavones have not been extensively explored.  Although glycitein is the only soy 
isoflavone with a methoxy group, other methylated isoflavones are found in plant material such 
as red clover.  Methylated isoflavones (glycitein, biochanin A, formononetin) may have greater 
anti-cancer activity than those without methyl groups (genistein, daidzein, equol) but this 
difference in isoflavone structure has not yet been studied.  
Most in vitro studies examining the anticancer effects of soy isoflavones have utilized
prostate cancer cell lines.  However, the epidemiological evidence suggests that the beneficial 
effects of soy are greatest during precancerous stages of the prostate carcinogenic process.  In 
fact, several dietary bioactive compounds have been shown to be most effective of specific 
stages during cancer (4, 32-34).  Although the literature provides invaluable information 
regarding the anticancer effects of soy isoflavones in cancer models, the anticancer effects of 
isoflavones in precancerous models have not been well characterized.  Therefore, this study 
examined the antiproliferative effects of methylated and nonmethylated isoflavones using a 
precancerous prostate epithelial cell model.  The WPE1-NB14 cell line mimics the precancerous 
stages of the prostate carcinogenic process.  This cell line was developed from the noncancerous 
RWPE-1 cell line.  RWPE-1 cells were developed from epithelial prostate cells and exposed to 
human papilloma virus-18 which enabled them to mimic prostate cells and their responses to 
hormones (35).  Briefly, RWPE-1 cells were exposed to N-methyl-N-nitrosourea (MNU).  The 
carcinogen, MNU, enables these cells to imitate cells in the early stages of cancer (35).  
8Methods
Cell Culture:  The human prostate precancerous epithelial cell line (WPE1-NB14) was obtained 
from the American Type Culture Collection (Rockville, MD).  WPE1-NB14 cells were
maintained in keratinocyte serum-free medium (GIBCO Laboratories, Grand Island, NY) 
supplemented with 50µg/ml bovine pituitary extract, 5% L-glutamine, 5ng/ml epidermal growth 
factor and penicillin/streptomycin (1.0%).  This cell line was maintained in a humidified 
incubator (5% CO2, 95% O2) at 37ºC.  
Proliferation:  Cells were plated in 48-well plates at an initial density of 8.0 x 103 cells per well 
with supplements.  Cells were treated with or without glycitein, biochanin A, formononetin,
genistein, daidzein and equol (0-50µM) and incubated for an additional 72 hours.  After 
incubation, cell proliferation will be determined by the 3-[4,5-dimethylthiazol-2-yl]-2-,5-
diphenyltetrazolium bromide (MTT) assay.  MTT was dissolved in PBS at 3mg/ml.  Briefly, 15 
µl of MTT solution was added to each well, followed by a three hour incubation.  After 
incubation, MTT-containing medium was removed and 150µl of 0.04M HCl in isopropanol was
added to each well to dissolve formazan crystals.  The concentration of formazen was quantified 
spectrophotometrically at 595nm.
Statistical Analysis: Statistical significance between groups was determined by one-way analysis 
of variance with Tukey’s post-hoc comparisons (SigmaStat software; Chicago, IL).  Data are 
presented as means ± relative standard error with alpha p<0.05 considered significant.
9Results
The methylated isoflavones reduced cell viability to a greater degree than the nonmethylated 
isoflavones.  Figure 3A shows that biochanin A significantly reduced cell viability by 21% and 
47% at 25µM and 50µM, respectively.  Figure 3B shows that formononetin significantly reduced 
cell viability by 36%, 42% and 47% at 12.5µM, 25µM, and 50µM, respectively.  Figure 3C 
shows that the methylated isoflavone, glycitein, had a significant reduction in cell viability by 
26%, 24% and 48% at 12.5µM, 25µM, and 50µM, respectively.  All of the methylated 
isoflavones had a significant reduction of cell viability in the 25µM and 50µM concentrations, 
with the greatest reduction in the 50µM.  Of the nonmethylated isoflavones, genistein had a 
significant reduction in cell viability by 19% at 50µM (figure 3D).  Similarly, figures 3E and 3F 
show that daidzein and equol significantly reduced cell viability at 50µM by 16% and 17%, 
respectively.  
Figure 3A.  Effects of biochanin A on WPE1-NB14 cell viability.  Cells were treated 
(72 hours) with biochanin A (0-50µM) and cell viability was determined by MTT 
assay.  * indicates a significant (p<0.05) reduction in viability compared to control.
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Figure 3B.  Effects of formononetin on WPE1-NB14 cell viability.  Cells were treated 
(72 hours) with formononetin (0-50µM) and cell viability was determined by MTT 
assay.  * indicates a significant (p<0.05) reduction in viability compared to control.
Figure 3C.  Effects of glycitein on WPE1-NB14 cell viability.  Cells were treated (72 
hours) with glycitein (0-50µM) and cell viability was determined by MTT assay.  * 
indicates a significant (p<0.05) reduction in viability compared to control.
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Figure 3D.  Effects of genistein on WPE1-NB14 cell viability.  Cells were treated (72 
hours) with genistein (0-50µM) and cell viability was determined by MTT assay.  * 
indicates a significant (p<0.05) reduction in viability compared to control.
Figure 3E.  Effects of daidzein on WPE1-NB14 cell viability.  Cells were treated (72 
hours) with daidzein (0-50µM) and cell viability was determined by MTT assay.  * 
indicates a significant (p<0.05) reduction in viability compared to control.
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Figure 3F.  Effects of equol on WPE1-NB14 cell viability.  Cells were treated (72 
hours) with equol (0-50µM) and cell viability was determined by MTT assay.  * 
indicates a significant (p<0.05) reduction in viability compared to control.
Discussion and Conclusions
The results of this study show that methylated isoflavones reduced precancerous cell 
viability to a greater extent than nonmethylated isoflavones.  The structural differences of the 
isoflavones may be responsible, in part, for these results.  Further research is needed to determine 
the mechanisms of these different isoflavones.  
Isoflavones are found mainly in legumes such as soy, lentils, beans and chickpeas (36).  
Soy, specifically, contains considerable amounts of genistein, daidzein and glycitein.  Biochanin 
A and Formononeitin are the isoflavones found in significant amounts in red clover (37).  Other 
sources of isoflavones are alfalfa roots (formononetin) and chickpeas (biochanin A) (38).  It has 
also been found that animal products, not only plant based products, contain isoflavones (39).  
However, these foods such as milk, eggs, and beef contain significantly less isoflavones than 
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plant based foods (39).  The possibility of introducing isoflavones into non-legumes has been 
suggested and with the decreasing costs of DNA sequencing, it is more possible now than ever 
before (38).  
Another direction for further research might be in observing how isoflavones impact 
precancerous prostate cell growth in vivo.  When methylated isoflavones, biochanin A and 
formononetin are ingested, they are absorbed into the gastrointestinal tract and travel through the 
portal vein to the liver.  In the liver, these isoflavones are demethylated and become their 
nonmethylated derivatives, genistein and daidzein.  Only then do they enter the circulatory 
system and eventually reach the prostate (37).  While these isoflavones are not in their most 
bioavailable form when they reach the prostate, it might be possible for the isoflavones to be 
remethylated enabling them to have a greater impact on cell viability. This might be achieved by 
the prostate’s own mechanisms or potentially by ingestion of a methyl donor such as S-sdenosyl-
L-methionine (SAMe).  SAMe is a nutritional supplement that is involved with many 
transmethylation reactions in the liver (40) as well as in the creation of the essential 
phospholipid, phosphatidylcholine, and neurotransmitters including epinephrine and dopamine 
(41).  This study demonstrates that there is a significant difference in the biological effects of 
methylated and nonmethylated isoflavones on WPE1-NB14 cells and will hopefully facilitate
further research in this area.
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